Juno Therapeutics Engineered T Cell Production Patent

ChangeBridge: Patent Grants - Pharma (A61K)

Published March 17th, 2026

Detected March 22nd, 2026

Summary

The USPTO has granted Juno Therapeutics, Inc. a patent (US12577285B2) for a process to produce engineered T cells for cell therapy. The patent covers methods for pooling and stimulating T cells, introducing genetic material, and cultivating them for therapeutic use.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12577285B2 to Juno Therapeutics, Inc. This patent covers a process for producing engineered T cells, specifically detailing methods for pooling CD4+ and CD8+ T cells, stimulating them, introducing recombinant polypeptides via transduction or transfection, and cultivating them to promote proliferation. The patent aims to provide an efficient and reliable method for generating genetically engineered T cells for cell therapy applications.

This patent grant signifies a new intellectual property right for Juno Therapeutics in the field of cell therapy. While not a regulatory rule imposing obligations on other entities, it establishes exclusive rights for the patent holder. Companies operating in the cell therapy space, particularly those involved in T cell engineering and manufacturing, should be aware of this patent to avoid potential infringement. The effective date of the grant is March 17, 2026, and the filing date was December 7, 2018.

Source document (simplified)

← USPTO Patent Grants

Process for producing a composition of engineered T cells

Grant US12577285B2 Kind: B2 Mar 17, 2026

Assignee

Juno Therapeutics, Inc.

Inventors

Mirna Mujacic, Ayu Rahardjo, Pascal Beauchesne, Kien Khuu-Duong, Ivie Aifuwa, Calvin Chan

Abstract

The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells and/or CD8+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for pooling enriched CD4+ and CD8+ cells, such as at a 1:1 ratio, and then incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

CPC Classifications

A61K 35/17 A61K 2039/5156 A61K 2039/5158 A61K 39/0011 C07K 14/7051 C07K 2319/03 C12N 5/0636 C12N 2510/00 C12N 2500/90 C12N 2501/00 C12N 2501/50 C12N 2501/599 C12N 2501/998